July 01, 2021
Targovax ASA appoints Dr Lone Ottesen as Chief Development Officer
Media
July 01, 2021
Nordic Nanovector Appoints Malene Brondberg as Interim Chief Executive Officer
June 24, 2021
Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors
June 23, 2021
InCarda Therapeutics Announces Positive End-of-Phase 2 Meeting with FDA for InRhythm™ for Treatment of Atrial Fibrillation
June 22, 2021
Nordic Nanovector Announces Initial Results from LYMRIT 37-05 Phase 1 Trial of Betalutin® in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
June 22, 2021
Targovax receives Fast Track designation for ONCOS-102 in melanoma
June 21, 2021
Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism
June 21, 2021
Doctrin raises €13 million to accelerate international expansion
June 17, 2021
BONESUPPORT receives “breakthrough device designation” for CERAMENT G for the indication trauma
June 17, 2021
Targovax announces completed enrollment in the phase 1/2 trial with ONCOS-102 in combination with durvalumab in patients with advanced colorectal cancer with peritoneal malignancies
